ClinicalTrials.gg
CompletedNCT01169701EVITAUpdated Dec 7, 2015Results posted

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

A Phase 4 interventional study of Everolimus and Tacrolimus in Renal Transplant, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-12-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients

02

Conditions studied

  • Renal Transplant

Keywords

  • Renal transplant, everolimus, cardiovascular profile, CNI-free immunosuppression, left ventricular hypertrophy, biopsy proved acute rejection (BPAR)
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's enrollment of 71 is below the median of 100 across 97 interventional studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received kidney transplant > 6 months and \< 3 years prior to study enrollment
  • Receiving regimen that includes tacrolimus and mycophenolic acid
  • Between 18 and 70 years of age
  • Willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Patients with an actual serum creatinine ≥ 2 mg/dl and/or ≤ 40 ml/min and/or proteinuria≥ 500mg/day
  • Patients who suffered from severe humoral and/or cellular rejection (≥ BANFF IIb, recurrent acute rejection or resistant acute rejection in the previous years
  • Patients who have severe hypercholesterolemia (>350 mg/dL; >9 mmol/L) or hypertriglyceridemia (>500 mg/dL; >8.5 mmol/L). Patients with controlled hyperlipidemia are acceptable.
  • Diabetic patients
  • Woman of who is planning to become pregnant or is pregnant and/or lactating who is unwilling to use effective means of
  • Presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements
  • Any other medical condition that, in the opinion of the site investigator based on recall or chart review would interfere with completing the study
  • Receiving any drug or have received any investigational drug within 30 days prior to study enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Active comparator
    Tacrolimus

    Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).

    Drug: Tacrolimus · Drug: Mycophenolic acid (MPA)

  • Experimental
    Everolimus

    Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.

    Drug: Everolimus · Drug: Tacrolimus · Drug: Mycophenolic acid (MPA)

Interventions

  • Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.

    Also known as: Certican®

  • Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.

    Also known as: Prograf®, Advagraf®

  • Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.

    Also known as: Myfortic®, Cell-Cept®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Left Ventricular Mass Index (LVMI)

    Left ventricular hypertrophy grade was assessed by echocardiogram where the left ventricular mass index was calculated. The presence of LVM was defined as \> 49.2 g/m\^2.7 in men and \>46.7 g/m\^2.7 in women. A negative change from baseline indicates improvement.

    Time frame: Baseline, Month 24

Secondary outcomes

  1. Change From Baseline in Mean 24 Hour Systolic and Diastolic Blood Pressure

    Blood pressure was measured using ambulatory blood pressure monitoring (ABPM). A negative change from baseline indicates improvement.

    Time frame: Baseline, Month 6, month 12, month 24

  2. Pulse Wave Velocity (PWV)

    Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.

    Time frame: Month 6, month 24

  3. Percentage of Participants With Major Cardiovascular Events (MACE)

    The percentage of participants who experienced MACE were reported. MACE included acute myocardial infarction, insertion or replacement of implantable defibrillator, peripheral vascular disorders, congestive heart failure, coronary artery bypass, other events, percutaneous coronary intervention and stroke.

    Time frame: Month 24

  4. Renal Function Measured by Serum Creatinine

    Serum samples were collected to analyze serum creatinine.

    Time frame: Month 6, month 12, month 24

  5. Renal Function as Measured by Creatinine Clearance

    Creatinine clearance was calculated using the Cockroft-Gault formula.

    Time frame: Month 6, month 12, month 24

  6. Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)

    Estimated GFR was caluclated using the modification of diet in renal disease (MDRD) formula.

    Time frame: Month 6, month 12, month 24

  7. Change From Baseline in Cardiovascular Biomarkers: Troponin I and Collagen Type 1 C-telopeptide (ICTP)

    Blood samples were collected to analyze Troponin I and collagen type 1 C-telopeptide (ICTP). A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  8. Change From Baseline in the Cardiovascular Biomarker, Glycosylated Hemoglobin (HbA1c)

    Blood samples were collected to analyze HbA1c. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  9. Change From Baseline in the Cardiovascular Biomarker, Myeloperoxidase (MPO)

    Blood samples were collected to analyze MPO. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  10. Change From Baseline in the Cardiovascular Biomarker, N-terminal Pro-brain Natriuretic Peptide Fraction (NT-proBNP)

    Blood samples were collected to analyze NT-proBNP. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  11. Change From Baseline in the Cardiovascular Biomarker, Type 1 Procollagen Amino-terminal-propeptide (PINP)

    Blood samples were collected to analyze PCR. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  12. Change From Baseline in Cardiovascular Biomarkers, C-reactive Protein (CRP)

    Blood samples were collected to analyze CRP. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 6, month 24

  13. Percentage of Participants With Biopsy-proven Acute Rejection (BPAR), Graft Loss, Death and Lost to Follow up

    The incidence of BPAR, graft loss, death and lost to follow-up events was calculated using relative frequency.

    Time frame: Month 24

07

Results

Posted Apr 30, 2015

Participant flow

Participant flow — Overall Study
MilestoneTacrolimusEverolimus
Started3635
Safety set3635
Intent to treat (itt) set3228
Completed3125
Not completed510
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject13
Withdrew: Adverse event12
Withdrew: Exclusion criteria20
Withdrew: Death01
Withdrew: Administrative problems01
Withdrew: Serious adverse event01
Withdrew: Sponsor decision01

Outcome measures

PrimaryChange From Baseline in Left Ventricular Mass Index (LVMI)

Left ventricular hypertrophy grade was assessed by echocardiogram where the left ventricular mass index was calculated. The presence of LVM was defined as \> 49.2 g/m\^2.7 in men and \>46.7 g/m\^2.7 in women. A negative change from baseline indicates improvement.

Time frame:
Baseline, Month 24
Reported as:
Mean · g/m^2.7
Change From Baseline in Left Ventricular Mass Index (LVMI)
g/m^2.7TacrolimusEverolimus
Change From Baseline in Left Ventricular Mass Index (LVMI)-6.071 ± 20.116-4.008 ± 17.610
SecondaryChange From Baseline in Mean 24 Hour Systolic and Diastolic Blood Pressure

Blood pressure was measured using ambulatory blood pressure monitoring (ABPM). A negative change from baseline indicates improvement.

Time frame:
Baseline, Month 6, month 12, month 24
Reported as:
Mean · mmHg
Change From Baseline in Mean 24 Hour Systolic and Diastolic Blood Pressure
mmHgTacrolimusEverolimus
Month 6 (n=31,29)-0.6 ± 9.13.2 ± 8.6
Month 12 (n=28,24)2.1 ± 6.92.7 ± 10.4
Month 24 (n=29,24)2.2 ± 10.62.0 ± 8.7
SecondaryPulse Wave Velocity (PWV)

Utilizing the SphygmoCor Device, ECG leads placed at the carotid and femoral arteries provided the measure of the pulse wave at that particular arterial location. The distance between the two vascular beds divided by the pulse wave time shift provided a measure of the pulse wave velocity.

Time frame:
Month 6, month 24
Reported as:
Mean · m/sec
Pulse Wave Velocity (PWV)
m/secTacrolimusEverolimus
Month 6 (n=31,30)7.01 ± 1.627.40 ± 1.62
Month 24 (n=28,25)7.58 ± 1.687.06 ± 1.74
SecondaryPercentage of Participants With Major Cardiovascular Events (MACE)

The percentage of participants who experienced MACE were reported. MACE included acute myocardial infarction, insertion or replacement of implantable defibrillator, peripheral vascular disorders, congestive heart failure, coronary artery bypass, other events, percutaneous coronary intervention and stroke.

Time frame:
Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Cardiovascular Events (MACE)
Percentage of participantsTacrolimusEverolimus
Percentage of Participants With Major Cardiovascular Events (MACE)0.000.00
SecondaryRenal Function Measured by Serum Creatinine

Serum samples were collected to analyze serum creatinine.

Time frame:
Month 6, month 12, month 24
Reported as:
Mean · mg/dl
Renal Function Measured by Serum Creatinine
mg/dlTacrolimusEverolimus
Month 6 (n=33,29)1.232 ± 0.2721.234 ± 0.360
Month 12 (n=32,28)1.231 ± 0.2781.256 ± 0.367
Month 24 (n= 31,26)1.217 ± 0.2351.260 ± 0.358
SecondaryRenal Function as Measured by Creatinine Clearance

Creatinine clearance was calculated using the Cockroft-Gault formula.

Time frame:
Month 6, month 12, month 24
Reported as:
Mean · mg/min
Renal Function as Measured by Creatinine Clearance
mg/minTacrolimusEverolimus
Month 6 (n=29,25)64.841 ± 16.16376.618 ± 27.708
Month 12 (n=28,25)65.037 ± 15.86673.363 ± 25.989
Month 24 (n=28,24)66.933 ± 13.26472.910 ± 23.926
SecondaryRenal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)

Estimated GFR was caluclated using the modification of diet in renal disease (MDRD) formula.

Time frame:
Month 6, month 12, month 24
Reported as:
Mean · mL/min/1.73m^2
Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m^2TacrolimusEverolimus
Month 6 (n=33,29)55.648 ± 11.24463.781 ± 18.380
Month 12 (n=32,28)57.757 ± 11.39161.225 ± 19.239
Month 24 (n=31,26)57.727 ± 10.49860.779 ± 17.023
SecondaryChange From Baseline in Cardiovascular Biomarkers: Troponin I and Collagen Type 1 C-telopeptide (ICTP)

Blood samples were collected to analyze Troponin I and collagen type 1 C-telopeptide (ICTP). A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · ng/ml
Change From Baseline in Cardiovascular Biomarkers: Troponin I and Collagen Type 1 C-telopeptide (ICTP)
ng/mlTacrolimusEverolimus
Troponin 1, Month 6 (n=27,30)0.000 ± 0.010-0.006 ± 0.026
Troponin 1, Month 24 (n=24,24)0.003 ± 0.026-0.007 ± 0.018
ICTP, Month 6 (n=27,30)0.049 ± 0.341-0.195 ± 0.234
ICTP, Month 24 (n=24,24)-0.035 ± 0.366-0.125 ± 0.323
SecondaryChange From Baseline in the Cardiovascular Biomarker, Glycosylated Hemoglobin (HbA1c)

Blood samples were collected to analyze HbA1c. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · Percentage of HbA1c
Change From Baseline in the Cardiovascular Biomarker, Glycosylated Hemoglobin (HbA1c)
Percentage of HbA1cTacrolimusEverolimus
Month 6 (n=20,22)0.015 ± 0.1840.159 ± 0.346
Month12 (n=22,20)0.045 ± 0.2370.185 ± 0.407
SecondaryChange From Baseline in the Cardiovascular Biomarker, Myeloperoxidase (MPO)

Blood samples were collected to analyze MPO. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · U/mL
Change From Baseline in the Cardiovascular Biomarker, Myeloperoxidase (MPO)
U/mLTacrolimusEverolimus
Month 6 (n=27,30)0.433 ± 2.189-0.093 ± 1.158
Month 24 (n=24,24)-0.329 ± 0.280-0.642 ± 0.972
SecondaryChange From Baseline in the Cardiovascular Biomarker, N-terminal Pro-brain Natriuretic Peptide Fraction (NT-proBNP)

Blood samples were collected to analyze NT-proBNP. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · pg/mL
Change From Baseline in the Cardiovascular Biomarker, N-terminal Pro-brain Natriuretic Peptide Fraction (NT-proBNP)
pg/mLTacrolimusEverolimus
Month 6 (n=27,30)21.604 ± 294.82-79.10 ± 401.44
Month 24 (n=24,24)-80.20 ± 424.24-193.3 ± 590.90
SecondaryChange From Baseline in the Cardiovascular Biomarker, Type 1 Procollagen Amino-terminal-propeptide (PINP)

Blood samples were collected to analyze PCR. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · ug/l
Change From Baseline in the Cardiovascular Biomarker, Type 1 Procollagen Amino-terminal-propeptide (PINP)
ug/lTacrolimusEverolimus
Month 6 (n=27,30)-13.82 ± 34.110-33.36 ± 33.227
Month 24 (n=24,24)-13.65 ± 40.675-28.17 ± 30.381
SecondaryChange From Baseline in Cardiovascular Biomarkers, C-reactive Protein (CRP)

Blood samples were collected to analyze CRP. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 6, month 24
Reported as:
Mean · mg/dl
Change From Baseline in Cardiovascular Biomarkers, C-reactive Protein (CRP)
mg/dlTacrolimusEverolimus
Month 6 (n=27,30)0.512 ± 2.3420.326 ± 1.129
Month 24 (n=24,24)0.100 ± 0.469-0.040 ± 1.683
SecondaryPercentage of Participants With Biopsy-proven Acute Rejection (BPAR), Graft Loss, Death and Lost to Follow up

The incidence of BPAR, graft loss, death and lost to follow-up events was calculated using relative frequency.

Time frame:
Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Biopsy-proven Acute Rejection (BPAR), Graft Loss, Death and Lost to Follow up
Percentage of participantsTacrolimusEverolimus
BPAR0.000.00
Graft loss0.000.00
Deaths0.000.00
Lost to follow-up3.130.00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus—5/36 (13.9%)21/36 (58.3%)
Everolimus—8/35 (22.9%)24/35 (68.6%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventTacrolimusEverolimus
Drug hypersensitivityImmune system disorders0/361/35
Oral herpesInfections and infestations0/361/35
PneumoniaInfections and infestations0/361/35
Respiratory syncytial virus infectionInfections and infestations0/361/35
Septic shockInfections and infestations0/361/35
UrosepsisInfections and infestations0/361/35
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/361/35
HaematuriaRenal and urinary disorders0/361/35
Renal impairmentRenal and urinary disorders0/361/35
Urinary tract obstructionRenal and urinary disorders0/361/35
Most frequent other events
Showing 10 of 31
Most frequent other events
EventTacrolimusEverolimus
Urinary tract infectionInfections and infestations7/361/35
Oedema peripheralGeneral disorders3/366/35
ProteinuriaRenal and urinary disorders0/365/35
HypertensionVascular disorders1/365/35
Escherichia urinary tract infectionInfections and infestations4/364/35
DiarrhoeaGastrointestinal disorders4/363/35
AnaemiaBlood and lymphatic system disorders0/363/35
Aphthous stomatitisGastrointestinal disorders0/363/35
HypercalcaemiaMetabolism and nutrition disorders3/361/35
LeukopeniaBlood and lymphatic system disorders0/362/35

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TacrolimusEverolimusTotal
Mean49.1 ± 12.047.4 ± 13.248.3 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)TacrolimusEverolimusTotal
Female161329
Male202242
08

Study locations

9 sites
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08025, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña 08003, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Madrid, Spain
09

References and documents

Publications

  • Cruzado JM, Pascual J, Sanchez-Fructuoso A, Seron D, Diaz JM, Rengel M, Oppenheimer F, Hernandez D, Paravisini A, Saval N, Morales JM; Evita Study Group. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. Transpl Int. 2016 Dec;29(12):1317-1328. doi: 10.1111/tri.12862. Epub 2016 Oct 17. PubMed 27648523 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2010
First posted
Jul 26, 2010
Start
Aug 2010
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Apr 30, 2015
Last update
Dec 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01169701
Responsible party
Sponsor
First posted
Jul 26, 2010
Start date
Aug 2010
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Apr 30, 2015
Last update
Dec 7, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion